Merck & Co.’s hangover from the withdrawal of its $2.5 billion a year arthritis drug Vioxx has lifted, according to Chief Executive Richard Clark, and the drugmaker is starting to flex its muscles again.
Bristol-Myers Squibb interim CEO James Cornelius weighs his Hawaiian vacation against taking over at the troubled drugmaker. He tells the Reuters Health Summit his name is not among the list of potential candidates for the permanent CEO job but he remains committed to staying on until a new chief is named.
As some executives play it close to the vest politically on election day, Universal Health’s CEO spells it out: Democrats in power in Congress are likely to boost coverage of the uninsured and lean toward more spending for seniors.
Amylin investors are bracing for new competition in the diabetes market from two Big Pharma powers: Merck and Novartis. But Amylin’s president is not worried. In fact — he’s breaking out the welcome mat.
Novartis’ head of corporate research is perfectly willing to look beyond the cost of good scientists — particularly in China where there is a growing pool of talent. When it comes to discovery research, talent and output outweighs cost every time, Paul Herrling tells the Reuters Summit in a phone interview.
Stemcell research funding proved to be a hot-button issue in the Congressional races leading up to election day this week — but it’s clear where Big Pharma stands on the new technology. Novartis’ head of corporate research told the Reuters Summit in a phone interview that he sees major breakthroughs in the U.S. if federal funding were ever to get approval.